Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12841582 | 0.86 | DPP4 (0.60) | DPP4CYP2D6CYP3A4CYP1A2KCNH2 | |
| SCHEMBL389683 | 0.84 | DPP4 (0.57) | DPP4CYP3A4OPRM1OPRK1 | |
| SCHEMBL8220276 | 0.83 | DPP4 (0.58) | DPP4CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL13206726 | 0.82 | DPP4 (0.47) | DPP4CYP3A4 | |
| SCHEMBL8216086 | 0.81 | DPP4 (0.56) | DPP4CYP3A4 | |
| SCHEMBL8210057 | 0.81 | DPP4 (0.58) | DPP4CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL15478762 | 0.81 | DPP4 (0.77) | DPP4CYP2D6CYP3A4CYP1A2KCNH2 | |
| SCHEMBL13142036 | 0.79 | DPP4 (0.46) | DPP4CYP2D6CYP3A4CYP1A2 | |
| SCHEMBL14141521 | 0.79 | DPP4 (0.53) | DPP4CYP2D6CYP3A4CYP1A2KCNH2 | |
| SCHEMBL16280709 | 0.78 | DPP4 (0.47) | DPP4CYP2D6CYP3A4CYP1A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114105889-B | Preparation method and application of key intermediate of DPP-IV inhibitor | 山东创新药物研发有限公司 | 2023-06-13 | — | — | CN | claimed |
| CN-110950840-B | Preparation method of trelagliptin succinate | 江苏天和制药有限公司 | 2022-03-15 | — | — | CN | claimed |
| CN-114105889-A | Preparation method and application of DPP-IV inhibitor key intermediate | 山东创新药物研发有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-109331019-B | Preparation method of composite trelagliptin succinate tablet | 安徽九华华源药业有限公司 | 2021-08-31 | — | — | CN | claimed |
| CN-112694465-A | Novel preparation process of trelagliptin succinate | 山东永丞制药有限公司 | 2021-04-23 | — | — | CN | claimed |
| CN-108794448-B | Preparation method of trelagliptin and salt thereof | 四川科伦药物研究院有限公司 | 2021-01-26 | — | — | CN | claimed |
| CN-109705089-B | Method for purifying compound | 浙江华贝药业有限责任公司 | 2020-04-10 | — | — | CN | claimed |
| CN-110950840-A | Preparation method of trelagliptin succinate | 江苏天和制药有限公司 | 2020-04-03 | — | — | CN | claimed |
| EP-3083580-A1 | A PROCESS FOR PREPARATION OF TRELAGLIPTIN SUCCINATE | Harman Finochem Limited (IN) | 2016-10-26 | — | — | EP | claimed |
| CN-105541793-A | Synthetic method of trelagliptin, trelagliptin synthesized through method and trelagliptin synthesis intermediate | HEBEI GUOLONG PHARMACEUTICAL CO LTD | 2016-05-04 | — | — | CN | claimed |
| WO-2015092805-A1 | A PROCESS FOR PREPARATION OF TRELAGLIPTIN SUCCINATE | HARMAN FINOCHEM LIMITED (IN) | 2015-06-25 | — | — | WO | claimed |
| US-8188275-B2 | hydrolase enzyme inhibors such as 2-(6-Chloro-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl)-benzonitrile | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-29 | — | — | US | claimed |
| US-20250066310-A1 | MULTI-SUBSTITUTED URACIL DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Hangzhou Adamerck Pharmlabs Inc. (CN) | 2025-02-27 | — | — | US | disclosed |
| EP-4458813-A1 | MULTI-SUBSTITUTED URACIL DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Hangzhou Adamerck Pharmlabs Inc. (CN) | 2024-11-06 | — | — | EP | disclosed |
| CN-116410143-A | Polysubstituted uracil derivative, preparation method and application thereof | 杭州奥默医药股份有限公司 | 2023-07-11 | — | — | CN | disclosed |
| WO-2023125792-A1 | MULTI-SUBSTITUTED URACIL DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 杭州奥默医药股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20050261271-A1 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. | 2005-11-24 | — | — | US | disclosed |
| EP-1586571-A1 | Dipeptidyl peptidase inhibitors | Takeda San Diego, Inc. (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2005095381-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095381-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066310-A1 | MULTI-SUBSTITUTED URACIL DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TYMP, UNG, UMPS | DPP4 396/4885CYP2D6 185/4885CYP3A4 227/4885 |
| US-20050261271-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP9 | DPP4 1/4885CYP2D6 413/4885CYP3A4 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.